These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 32674929)

  • 1. Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?
    Machiels JD; Bleeker-Rovers CP; Ter Heine R; Rahamat-Langendoen J; de Mast Q; Ten Oever J; Bousema T; van Crevel R; Wertheim HF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106056. PubMed ID: 32674929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxychloroquine in Covid-19: Does the end justify the means?
    Yakoub-Agha I
    Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
    Juurlink DN
    CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021
    [No Abstract]   [Full Text] [Related]  

  • 5. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
    Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Tissot Dupont H; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D
    Int J Antimicrob Agents; 2020 Jul; 56(1):105949. PubMed ID: 32205204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
    Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
    Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
    Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
    Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France.
    Million M; Lagier JC; Gautret P; Colson P; Fournier PE; Amrane S; Hocquart M; Mailhe M; Esteves-Vieira V; Doudier B; Aubry C; Correard F; Giraud-Gatineau A; Roussel Y; Berenger C; Cassir N; Seng P; Zandotti C; Dhiver C; Ravaux I; Tomei C; Eldin C; Tissot-Dupont H; Honoré S; Stein A; Jacquier A; Deharo JC; Chabrière E; Levasseur A; Fenollar F; Rolain JM; Obadia Y; Brouqui P; Drancourt M; La Scola B; Parola P; Raoult D
    Travel Med Infect Dis; 2020; 35():101738. PubMed ID: 32387409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
    Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
    Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
    Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
    Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
    Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
    [No Abstract]   [Full Text] [Related]  

  • 12. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
    Rosendaal FR
    Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928
    [No Abstract]   [Full Text] [Related]  

  • 14. The COVIRL-001 Trial: A multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: A structured summary of a study protocol for a randomised controlled trial.
    Feeney E; Wallace D; Cotter A; Tinago W; McCarthy C; Keane D; Hussain R; Alvarez Barco E; Doran P; Mallon P
    Trials; 2020 May; 21(1):430. PubMed ID: 32450915
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxychloroquine and Azithromycin to Treat Patients With COVID-19: Both Friends and Foes?
    Mégarbane B; Scherrmann JM
    J Clin Pharmacol; 2020 Jul; 60(7):808-814. PubMed ID: 32434282
    [No Abstract]   [Full Text] [Related]  

  • 16. Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
    Li C; Cheng G
    Front Immunol; 2020; 11():1969. PubMed ID: 32849658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
    Capucci A; Santarelli A; Bartolomei M; Paolizzi C; Biagetti C; Dappozzo A; Piovaccari G
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):922-923. PubMed ID: 32740441
    [No Abstract]   [Full Text] [Related]  

  • 18. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
    Fantini J; Chahinian H; Yahi N
    Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
    Kim AHJ; Sparks JA; Liew JW; Putman MS; Berenbaum F; Duarte-García A; Graef ER; Korsten P; Sattui SE; Sirotich E; Ugarte-Gil MF; Webb K; Grainger R;
    Ann Intern Med; 2020 Jun; 172(12):819-821. PubMed ID: 32227189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology.
    Pani A; Lauriola M; Romandini A; Scaglione F
    Int J Antimicrob Agents; 2020 Aug; 56(2):106053. PubMed ID: 32534189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.